During the high profile JPMorgan Healthcare Conference, Motley Fool health care bureau chief Brenton Flynn took a moment to look back at some of the interesting things he observed. In this segment of the video, he discusses a prostate-cancer-focused biotech Medivation (MDVN) and its presentation -- and three potential share price catalysts.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
3 Catalysts for Medivation
By Brenton Flynn
–
Jan 11, 2013 at 10:59AM
NASDAQ: MDVN
Medivation, Inc.
Here are 3 key things that could drive Medivation shares.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Dendreon and Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Medivation, Inc.
MDVN
Johnson & Johnson
JNJ
$156.58
(-0.15%)
$0.24
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
2 Biotech Stocks that Turned $8,000 into over $250,000
Is Pfizer Paying Too Much to Buy Medivation?
What's Up With Mylan's EpiPen Pricing?
3 Stocks Up Over 1,000% in the Past 5 Years
What Pfizer Gets in Its $14 Billion Medivation Deal
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.